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E-mail address: Rajendra.Kumar-Singh@tufts.edu.The majority of recent preclinical gene therapy studies targeting the retina have used adeno-associated
virus (AAV) as the gene transfer vector. However, AAV has several limitations including the ability to gen-
erate innate inﬂammatory responses, the ability to cause insertional mutagenesis at a frequency of up to
56% in some tissues and a limited cloning capacity of 4.8 Kb. Furthermore, AAV is known to generate lim-
iting immune responses in humans despite the absence of similar immune responses in preclinical canine
and murine studies. Three clinical trials to treat Leber’s congenital amaurosis using AAV are under way. A
clinical trial to treat Stargardt’s using lentivirus vectors has also been recently announced. However, very
limited evidence currently exists that lentivirus vectors can efﬁciently transduce photoreceptor cells. In
contrast, very few preclinical ocular gene therapy studies have utilized adenovirus as the gene therapy
vector. Nonetheless, the only two ocular gene therapy clinical trials performed to date have each used
adenovirus as the vector and more signiﬁcantly, in these published trials there has been no observed
serious adverse event. These trials appear to be poised for Phase II/III status. Activation of cytotoxic T
lymphocytes limits duration of transgene expression in the retina from ﬁrst generation adenovirus
vectors. However, an advanced class of adenovirus vectors referred to as Helper-dependent Adenovirus
(Hd-Ad) have recently been shown to be capable of expressing transgenes in ocular tissues for more than
one year. Hd-Ad vectors have many properties that potentially warrant their inclusion in the retinal gene
therapy toolbox for the treatment of retinal degenerative diseases.
 2008 Elsevier Ltd. All rights reserved.1. Progress in retinal gene therapy
During the previous decade, substantial progress has been made
in preclinical ocular gene therapy. Of particular note are several
studies demonstrating long-term correction of the visual defect
in animal models of Leber’s congenital amaurosis (LCA) (Acland
et al., 2001; Le Meur et al., 2007; Narfstrom et al., 2003). In each
of these studies, an adeno-associated virus (AAV) vector was used
to deliver the RPE65 cDNA to the retinal pigment epithelium (RPE)
of LCA dogs. These studies have led to the initiation of two LCA
clinical trials in the United States and one in the United Kingdom.
The majority of additional gene therapy studies demonstrating
long-term rescue of retinal degeneration in animal models have
also focused on the delivery of transgenes to the RPE (Tschernutter
et al., 2005). However, some disorders such as retinitis pigmentosa
(RP), are much more common than LCA and are typically associ-
ated with degeneration of the rod photoreceptor cells due to muta-
tions in genes expressed exclusively in those cells (Hartong,
Berson, & Dryja, 2006). In contrast to RPE-associated diseases,
there are no published studies thus far demonstrating evidence
of efﬁcacious and long-term somatic rescue of rod photoreceptor
degeneration caused by mutations in photoreceptor-speciﬁc genes.
While the rods don’t play a signiﬁcant role in daylight vision, theirll rights reserved.degeneration leads to the eventual loss of cones; hence the rods are
important target cells for retinal gene therapy. Herein, I identify
the current barriers and potential solutions for progress in gene
therapy for rod photoreceptor degeneration and ocular gene ther-
apy in general. In brief, given the availability of a large number of
well-characterized animal models of retinal degeneration (Chang
et al., 2005) along with our substantial knowledge of the genetic
basis underlying retinal degeneration, the major obstacles for suc-
cessful retinal gene therapy are a lack of appropriate gene transfer
vectors that are capable of delivering transgenes efﬁciently and in
the appropriate context to retinal cells. A variety of reviews (Auric-
chio & Rolling, 2005; Bainbridge, Tan, & Ali, 2006; Rolling, 2004;
Surace & Auricchio, 2007) summarizing successful preclinical reti-
nal gene transfer have already been published and hence those
studies are not discussed here. Instead, here we focus almost
exclusively on issues that were least discussed previously, i.e. the
major vector-associated barriers that need to be overcome in order
to achieve safe and efﬁcacious retinal gene therapy in the clinic.
Before a discussion of each speciﬁc barrier that needs to be
overcome, it is worth addressing what are the properties of the
ideal gene transfer vector for retinal cells. A case will be made
for such a hypothetical vector as having the following properties:
non-integrating or episomal existence in the nucleus, high levels
of tropism for the target cell in post-mitotic retina, a large trans-
gene cloning capacity, long-term transgene expression, lack of an
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necessary. The discussion of current limitations will be focused pri-
marily on the most commonly used vectors in ocular gene therapy
thus far, namely AAV, Lentivirus (Lv) and Adenovirus (Ad). In con-
trast to previously published reviews, a case will be presented here
for why Ad should also be considered as a potential gene therapy
vector for ocular diseases. The objective is not to claim that Ad is
superior to AAV or Lv but rather to highlight recent developments
in Ad vector technology and its application in ocular tissues that
warrant further consideration.2. Integrating vectors cause insertional mutagenesis
The retina is generally considered to be comprised entirely of
post-mitotic cells. Hence, dilutional loss of an episomal transgene
due to cell division is not a signiﬁcant barrier in retinal gene ther-
apy. Historically, it has been assumed that long-term transgene
expression requires integration of the transgene into the nuclear
genome. As will be discussed, integration of the transgene is not
a requirement for long-term transgene expression.
One of the most remarkable studies demonstrating that gene
therapy is a viable approach for treating genetic disease in humans
involved the successful treatment of eleven children suffering from
Severe Combined Immunodeﬁciency Disease (SCID)-X1 (Cavazz-
ana-Calvo et al., 2000). In those studies, the integrating Moloney
retrovirus vector was utilized to deliver a cDNA encoding the cc
cytokine receptor ex vivo. This integrating vector however, also
caused insertional mutagenesis, leukemia in four and death in
some of those same patients (Kaiser, 2003). Hence, based on at
least these studies, the case for the absolute need for integrating
vectors is weakened should persistence of gene expression be pos-
sible without integration. Indeed, after the clinical trials were ini-
tiated, it was discovered that mice treated with an analogous
retrovirus vector also developed leukemia-like symptoms (Li et
al., 2002). There is signiﬁcant debate whether the human clinical
trials were conducted prematurely given the data obtained from
animals at a later date. An argument has been made that these
unfortunate results were due to the unique transgene utilized in
the vector, since other similar trials in the UK utilizing retrovirus
based gene transfer did not have insertional mutagenesis noted
in them. Accordingly, it must be noted that the dose of the virus
administered (as well as the absolute number of successfully trans-
duced stem cells infused into these patients) was at a level not pre-
viously achieved in other retrovirus trials. The UK trials were
continued and those trials also ultimately led to T-cell leukemia
in some patients. For purposes of this discussion, it should be noted
however that gene transfer in these trials was performed ex vivo in
proliferating cells, a condition not analogous to post-mitotic retinal
tissues. However, the need for cell proliferation is not a strict
requirement for insertional mutagenesis.
The issue of insertional mutagenesis has now also become sig-
niﬁcant relative to AAV based gene transfer. Wild-type AAV vectors
naturally integrate at a unique site in human chromosome 19
known as AAVS1 (Kotin et al., 1990). Site-speciﬁc recombination
is mediated through the AAV Rep proteins (Snyder, Im, & Muz-
yczka, 1990). In order to make space for the transgene, recombi-
nant AAV vectors lack Rep encoding genes. Despite loss of Rep,
these vectors still integrate, but now randomly in human cells
(Ponnazhagan et al., 1997). For example, in studies involving
AAV-mediated gene transfer to the liver, it has been shown that
the predominant form of AAV genomes are present as episomal
concatemers. Further studies revealed multiple integration sites
in the hepatocyte genome-sites that have been mapped and found
to be localized to active genes with integration adjacent to cancer-
related genes occurring at a rate of 3.5% (Nakai et al., 2005). Inaddition, AAV vectors integrate on chromosome 1 and exist in
the nucleus as mini circles (Schnepp, Jensen, Chen, Johnson, &
Clark, 2005).
Insertional mutagenesis caused by recombinant AAV vectors
was suspected in some earlier studies involving the delivery of b-
glucuronidase (GUSB) to mucopolysaccharidosis type VII (MPSVII)
mice (Donsante et al., 2001). Three out of ﬁve mice treated with re-
combinant AAV developed hepatocellular carcinomas and angio-
sarcomas, indicating a possible correlation of tumor formation
with AAV. The consensus in the AAV gene therapy community
was that these data were likely speciﬁc to MPSVII mice, which
may for unknown reasons be highly susceptible to carcinomas
(Marshall, 2001). However, in some more recently published stud-
ies it has been found that normal mice injected with AAV express-
ing GUSB develop hepatocellular carcinoma at the alarmingly high
rate of 56%. These investigators identiﬁed changes in gene expres-
sion proﬁles on chromosome 12 in the proximity of the mir-341
microRNA transcript and implicated insertional mutagenesis as
the source of hepatocellular carcinomas (Donsante et al., 2007).
No tumors were observed in transgenic mice over-expressing
GUSB. Mice injected with AAV vectors devoid of a transgene-regu-
lating promoter developed carcinomas at a rate of 33% (Donsante
et al., 2007), directly implicating AAV as the potential source of
the carcinomas. It should be mentioned however, that in this study
normal uninjected mice also developed carcinomas, but at a sub-
stantially lower frequency of 8.3% (Donsante et al., 2007). This
study has rekindled the debate about the safety of AAV vectors.
The counter arguments offered are that the latest studies were per-
formed in newborn mice that might be more susceptible to carci-
nomas due to the ease of whole body transduction (Kay, 2007).
Relevant to our discussion, these observations do raise the ques-
tion whether integrating vectors such as AAV or lentivirus are a
good platform for retinal gene therapy if episomal vectors could
efﬁciently express transgenes long-term. Development of non-
integrating Lv vectors is now being pursued (Yanez-Munoz et al.,
2006), in part prompted by the insertional mutagenesis observed
in the SCID-X1 clinical trials.
In July 2007, a patient being treated for rheumatoid arthritis by
AAV-mediated delivery of tgAAC94, an inhibitor of tumor necrosis
factor a, died unexpectedly, temporarily raising additional fears
that vectors such as AAV are perhaps not as safe as initially pre-
sumed. An expert panel failed to deﬁnitively rule out the role of
AAV in that death but also failed to ﬁnd evidence directly implicat-
ing AAV (Kaiser, 2007). Hence, those trials have resumed.
While recombinant AAV and Lv integrate randomly into the
genome of human cells, Ad is generally a non-integrating vector
that persists in the nucleus as an episome (Russell, 2000). How-
ever, at high multiplicities of infection, Ad can also integrate (Neu-
mann & Doerﬂer, 1981) but integration can in some cases be
engineered to occur site-speciﬁcally (Wang & Lieber, 2006).3. Photoreceptor tropism is dictated by stage of retinal
development
The majority of studies attempting to rescue rod photoreceptor
degeneration in mouse models of RP have administered the vector
during retinal development and differentiation between post-natal
days 3 and 21 and not the post-mitotic adult retina (Ali et al., 2000;
Bennett et al., 1996; Jomary, Vincent, Grist, Neal, & Jones, 1997;
Kumar-Singh & Farber, 1998; Pawlyk et al., 2005). While the need
for this timing was based primarily on achieving therapeutic inter-
vention prior to the onset of signiﬁcant photoreceptor degenera-
tion, results from these studies have limited relevance for gene
therapy in the human retina unless these vectors can be demon-
strated to also infect fully developed photoreceptors and not only
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because the tropism of viral vectors for different cell types is dic-
tated by stage of retinal development. Retinal development at
post-natal days 3–7 in mice is roughly equivalent to the 2nd tri-
mester of retinal development in utero in humans (Reh, 2006). In-
deed, in newborn mice the retina is still undergoing signiﬁcant cell
proliferation, providing for the opportunity of vectors requiring cell
division for transductional capability (i.e. retroviruses) to have a
chance at showing efﬁcacy. Rod birth in neonatal mice continues
up to p11 (Cepko, Austin, Yang, Alexiades, & Ezzeddine, 1996). This
is in contrast to human retina where the entire central retina is free
of cell division by fetal week 12 (Georges, Madigan, & Provis, 1999;
Penfold & Provis, 1986) and the life-time supply of rod photorecep-
tors is largely completed in utero (Linberg & Fisher, 1990). Retrovi-
rus vectors can infect only dividing cells and hence can be used to
label photoreceptors (Price, Turner, & Cepko, 1987) and other ret-
inal cells during development when the nuclear membrane is
breaking down and allowing nuclear access to the retrovirus gen-
ome. These same retrovirus vectors do not transduce adult murine
retina that is post-mitotic. Similarly, while AAV, Ad and Lv can all
transduce both photoreceptors and RPE very efﬁciently during
murine retinal development, none of these vectors can efﬁciently
transduce rod photoreceptors in the adult murine retina but are
limited primarily to transducing the RPE after subretinal adminis-
tration (Ali et al., 1996; Cashman, Sadowski, Morris, Frederick, &
Kumar-Singh, 2002; Pang et al., 2004, 2006). This signiﬁcant shift
in tropism coincides with the end of photoreceptor birth, at
approximately p10 and complete differentiation of the murine
retina by p21 (Cepko et al., 1996). Since each of these vectors can
infect post-mitotic cells, the lack of efﬁcacy may be due to a
down-regulation in the respective viral receptors present on the
photoreceptor plasma membrane. Similar observations have been
made for muscle cells, where myoblasts in neonatal mice are more
amenable to infection by Ad relative to the more developed and
specialized myotube ﬁbers found in adults (Acsadi et al., 1994).
The limitation of RPE tropism can be overcome by the method
of pseudotyping, involving exchange of the naturally occurring
coat proteins of the viral vector with heterologous proteins from
a virus that does have a tropism for photoreceptors. For example,
AAV serotype 2 (AAV2) can be pseudotyped with AAV8 coat pro-
teins to enhance photoreceptor tropism in adult mice (Allocca et
al., 2007). Interestingly, while the majority of studies in mice
and rats expressing GFP from a CMV promoter in the context of
AAV2 indicate that transgene expression is primarily in the RPE
and very limited in the photoreceptors, the same experiments in
monkeys indicate that transduction is almost exclusively of the
rod photoreceptors (Bennett et al., 1999). These data would indi-
cate that either the CMV promoter is not active in the RPE of mon-
keys or that AAV2 does not transduce the RPE of monkeys. In a
similar study, CMV regulated GFP in the context of AAV2 did
not reveal exclusive transduction of rod photoreceptors by this
vector (Le Meur et al., 2005). In this latter study, the investigators
attributed low levels of GFP in the RPE due to quenching of GFP by
pigment in the RPE (Le Meur et al., 2005). An alternative explana-
tion for these observations is that high levels of RPE transduction
by AAV2 is toxic and incidentally atrophy of RPE cells was re-
ported in the former monkey studies (Bennett et al., 1999). More
recently, dropout of GFP-positive RPE cells and retinal pathology
has been observed in AAV-transduced RPE in monkeys (Vanden-
berghe et al., 2007). Clearly, data obtained using non-human pri-
mates does not correlate well with small animal studies or those
performed in dogs. However, not all studies have been performed
with GMP grade vectors and that may in part explain the varying
results. Nonetheless, given that all currently ongoing LCA clinical
trials are using AAV2 as the gene transfer vector, and the non-hu-
man primate eye is closer in structure and physiology to the hu-man eye than are eyes of rodents or dogs, further studies on the
performance of AAV2 in non-human primate retina may be
warranted.
Lv has been used to transduce the retina of rat or mouse pups
and found to efﬁciently deliver GFP to photoreceptors, but in
adults, transduction primarily of the RPE is observed (Miyoshi,
Takahashi, Gage, & Verma, 1997; Pang et al., 2006). Such vectors
have been used to slow rod photoreceptor degeneration in rd1
mice but only when the vector is introduced in neonates (Takah-
ashi, Miyoshi, Verma, & Gage, 1999). Importantly, such vectors
do not transduce adult murine photoreceptors efﬁciently (Bain-
bridge et al., 2001) and hence are not predicted to be very useful
in human photoreceptor gene therapy except if they were to be
administered in utero, currently an untenable task. In one study,
photoreceptor transduction in adult murine retina has been
achieved using a lentivirus vector pseudotyped with equine infec-
tious anemia virus (EIAV) but the levels of photoreceptor transduc-
tion were described by the investigators as ‘variable’ (Balaggan
et al., 2006). In another study, VSV-G pseudotyped lentivirus was
also shown to transduce photoreceptors in adult rats but again
the levels of transduction were described by the authors as ‘spo-
radic’ (Bemelmans et al., 2005). Nonetheless, a clinical trial for
Stargardt’s disease using lentivirus vectors (Stargen, Oxford Bio-
medica) has been announced to begin within the next one year de-
spite the apparent failure of lentivirus-mediated transduction of
photoreceptors—the target cells in those clinical trials. A variety
of promoter constructs for photoreceptor-speciﬁc gene expression
using EIAV vectors have been developed, but transgene expression
from those vectors was tested by administration of vector in neo-
natal murine retina at p5 (Nicoud et al., 2007). Administration of
lentivirus expressing GFP from a rhodopsin promoter into adult
rats leads to poor gene expression in the photoreceptors, conﬁrm-
ing that gene transfer is limited primarily at the level of transduc-
tion and not gene expression per se (Bemelmans et al., 2005;
Miyoshi et al., 1997). Hence, currently available evidence may indi-
cate that lentivirus vectors are not yet signiﬁcantly developed for
delivery of transgenes to photoreceptors and hence signiﬁcant fur-
ther development of these vectors may be necessary prior to the
initiation of clinical trials targeting photoreceptors. Interestingly,
the studies documenting ‘variable’ transduction of photoreceptors
by Lv were also performed by Oxford Biomedica (Balaggan et al.,
2006; Nicoud et al., 2007). One assumes that Stargardt’s patients
enrolled in a clinical trial will be treated with an as yet unpub-
lished lentivirus vector that does efﬁciently transduce post-mitotic
photoreceptors.
Similar to AAV and Lv, Ad also transduces primarily the RPE in
adult murine retina despite being able to transduce photoreceptors
in neonatal retina (Pang et al., 2004). Indeed, some of the ﬁrst stud-
ies demonstrating a delay in rod photoreceptor degeneration uti-
lized Ad as the gene transfer vector (Bennett et al., 1996; Kumar-
Singh & Farber, 1998). In those studies, Ad was administered prior
to p10—a stage prior to the purported shift in tropism of Ad from
photoreceptors/RPE to only RPE. Pseudotyping of Ad by exchanging
the ﬁber protein has led to an improvement in tropism towards
photoreceptors but those vectors still preferentially transduced
the RPE, and antibodies against GFP were necessary to detect GFP
in the photoreceptors (Mallam, Hurwitz, Mahoney, Chevez-Barrios,
& Hurwitz, 2004). In another study, photoreceptor transduction
was achieved via the intravitreal route using an adenovirus vector
pseudotyped with ﬁber from serotype 37 (Von Seggern et al.,
2003). This is the only study demonstrating that the 80 nm Ad cap-
sid can traverse the inner retina and reach the photoreceptors
when administered via the intravitreal route. These data are unex-
pected and surprising given that AAV vectors with a diameter of
23 nm fail to transduce photoreceptors via the intravitreal route.
Nonetheless, should the intravitreal route of photoreceptor
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photoreceptor diseases would be signiﬁcantly advanced, as intravi-
treal procedures are routine in the clinic and used currently for the
administration of lucentis to patients suffering from age-related
macular degeneration. One study has recently shown that deletion
of the integrin-binding RGD domain in Ad penton base allows Ad to
infect photoreceptors, generally comparable to that seen with
pseudotyped AAV vectors. While those studies were done with ﬁrst
generation Ad vectors that are hampered by a 7Kb cloning capac-
ity, very strong levels of GFP was observed throughout the retina
(Cashman, McCullough, & Kumar-Singh, 2007) but transgene
expression was still strongest in the RPE.4. The need for a large transgene cloning capacity
Any transgene being expressed in rod photoreceptors must be
tightly regulated in terms of gene expression and cell speciﬁcity.
It has been known for some time that 5-fold expression of even
normal gene products in rod photoreceptors leads to retinal degen-
eration (Olsson et al., 1992). In the case of the most commonly
mutated gene in RP, namely rhodopsin, as little as 23% expression
above normal levels of the wild-type gene leads to retinal degener-
ation (Tan et al., 2001). Over-expression of peripherin/RDS deliv-
ered ectopically by an AAV vector to normal mice also led to
retinal degeneration whereas AAV-delivered GFP did not (Sarra et
al., 2001). Each of the above studies support the hypothesis that
over-expression of normal transgenes in rod photoreceptors is del-
eterious. Examination of mice that are heterozygous for the rho-
dopsin-null allele indicates that haploinsufﬁciency leads to
disorganized photoreceptor outer segments and reduced electrore-
tinograms and slow retinal degeneration (Liang et al., 2004).
Hence, it would appear that there is a narrow range of gene expres-
sion that can be tolerated by rod photoreceptors to remain func-
tional. One approach to control gene expression levels is the use
of inducible systems that rely on an exogenous drug e.g. doxycy-
cline to regulate the transgene-associated promoter (Goverdhana
et al., 2005). While such approaches are very useful for studying
temporally regulated expression of transgenes in animals includ-
ing non-human primates (Stieger et al., 2006), it is unlikely that
this approach will be a practical solution for RP patients. This is
in part because such inducible systems are often immunogenic
(Guiner, Stieger, Snyder, Rolling, & Moullier, 2007; Lena, Giannetti,
Sporeno, Ciliberto, & Savino, 2005) and because these approaches
would rely on monitoring transgene expression on a regular basis
in a non-invasive manner in order to gauge the amount of gene-in-
ducer drug to administer. Practical and non-invasive methods to
measure, for example, rhodopsin expression levels in RP patients
are currently limited. One practical solution to this problem is
the use of native gene regulatory elements to control gene expres-
sion. Such gene regulatory elements should theoretically partici-
pate in the natural feedback mechanisms present in the cell to
regulate gene expression. Such gene control elements tend to be
large relative to the limited cloning capacity of AAV—4.8 Kb, Lv—
7 Kb or early generation Ad vectors—7 Kb (Verma & Somia,
1997). In fact, once accommodation for the cDNA and polyadenyl-
ation sequences has been made, little room is left for large gene
regulatory elements in any of these vectors.
Limited evidence exists for rod photoreceptor-speciﬁc trans-
gene expression in the context of gene therapy. For example, short
rhodopsin promoters of approximately 470 bp are known to ex-
press transgenes in both rods and cones (Glushakova et al.,
2006). One study has reported rod speciﬁc transgene expression
using a 235 bp opsin promoter (Khani et al., 2007). In the case of
RP, it is plausible that ectopic and unregulated expression of genes
such as rod opsin in the cones will lead to dominant negative phe-notypes. Indeed, retinal degeneration in rd7 mice, a genetic model
of enhanced S-cone syndrome, is attributed to rod photoreceptors
expressing both rod and cone speciﬁc genes (Corbo & Cepko, 2005).
Rod or cone speciﬁc transgene expression has been achieved in the
context of transgenic animals (Lem, Applebury, Falk, Flannery, & Si-
mon, 1991; Li et al., 2005) and the promoters utilized are typically
larger than can be accommodated by currently available viral vec-
tors. Despite the general need for cell-speciﬁc gene expression,
there is a potential need for driving transgene expression in both
rods and cones, such as for X-linked RP (RP3) (Hong et al., 2000).
While short rhodopsin kinase promoters (Khani et al., 2007) can
express transgenes in both rods and cones, ultimately it may be
preferable to use a promoter that is native to the transgene (for
reasons discussed above). Recently, a 4.7 Kb rod opsin promoter
was used to drive transgene expression in the context of an Ad vec-
tor but it remains to be determined whether even this length of
promoter is rod speciﬁc in the context of gene therapy (Cashman
et al., 2007). Furthermore, for some ocular diseases the cDNA of
interest is simply too large to be accommodated in AAV vectors
even without large gene regulatory elements. Examples include
but are not limited to ABCR, CEP290 and myosin VIIa, each cDNA
of which is greater than 4.8 Kb. Clearly, in order to achieve rod pho-
toreceptor-speciﬁc and regulated tansgene expression, vectors
with larger cloning capacity than currently available are needed.
One potential solution to the problem of a limited cloning capac-
ity is the approach of trans splicing of a gene split betweenmultiple
AAV vectors (Lai et al., 2005). At this time, trans splicing is relatively
inefﬁcient and requires gene sequence-speciﬁc modiﬁcations.
Nonetheless, such approaches do warrant further investigation.
One potential solution to the barrier of a limited cloning capac-
ity of AAV, Lv and Ad is the use of Helper-dependent Adenovirus
(Hd-Ad) vectors that have a cloning capacity of 36 Kb (Parks et
al., 1996). Such vectors are structurally analogous to recombinant
AAV vectors since they contain only the transgene of interest,
ﬂanked by the Ad inverted terminal repeats (Fig. 1). As will be dis-
cussed below, such vectors have many additional properties that
render these vectors interesting for future gene therapy.5. Vector-associated immune response
Long-term transgene expression is a requirement for treatment
of slowly progressive degenerative diseases such as RP. If a vector
is to achieve long-term transgene expression, it must evade the im-
mune response. The immune response is usually directed towards
viral proteins but may also be directed towards the transgene
product if the immune system is naïve towards that protein—as
could occur in for example rhodopsin-null patients carrying pre-
mature stop codons in the rhodopsin mRNA. Such patients will
never have been exposed to wild-type rhodopsin epitopes and
may generate immune responses against such proteins even in
the immune privileged retina. This scenario may be even more rel-
evant in the retina of patients with retinal degeneration that may
be prone to leakage of retinal antigens due to disease. As gene ther-
apy requires the delivery of the wild-type gene/protein, we are
limited at this time to addressing only the immune response asso-
ciated with the vector. The general consensus in the retinal gene
therapy ﬁeld is that AAV is the least immunogenic of the viral gene
transfer vectors available. General enthusiasm for AAV initially
emanated from the observation that AAV could persistently ex-
press LacZ without activation of cytotoxic T lymphocytes (CTLs)
after intramuscular injection into mice (Fisher et al., 1997; Kessler
et al., 1996). Persistent transgene expression was subsequently ob-
served in retinal gene transfer (reviewed in (Allocca, Tessitore,
Cotugno, & Auricchio, 2006)). However, there is signiﬁcant evi-
dence that AAV can cause an immune response that is limiting to
Fig. 1. Capsid and genomic structures of recombinant adeno-associated Virus (AAV),
1st generation adenovirus and Helper-dependent adenovirus, emphasizing differ-
ences in cloningcapacity for the recombinant transgeneexpressioncassette.Whereas
1st generation Ad vectors have deletions in E1 and E3, second-generation Ad vectors
have deletions in E4, E2 etc. in addition to E1 and E3. ITR, inverted terminal repeat.
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fail to generate such responses in dogs and mice. For example,
while sustained factor IX expression was achieved over several
years in dog and murine models of hemophilia B (Herzog et al.,
1999; Snyder et al., 1999), transgene expression declined rapidly
during clinical trials for hemophilia (Manno et al., 2006). No anti-
body to factor IX was found in those patients but T-cell responses
to AAV capsid were documented, implicating the vector as the pri-
mary cause for loss of transgene expression. Partial immune priv-
ilege of the ocular environment might allow such studies to not
be directly comparable to retinal gene therapy (Bennett, 2003).
However, inﬂammatory responses, neutralizing antibodies and
RPE atrophy following delivery of AAV into the subretinal space
of non-human primates has been documented (Bennett et al.,
1999). T-cell responses to AAV capsid and local dropout of trans-
gene expression (GFP) have also been documented after subretinal
injection of AAV in non-human primates (Vandenberghe et al.,
2007). Again, these data may need to be further considered prior
to the initiation of additional clinical trials using AAV in ocular
gene therapy.
Adenovirus vectors have received signiﬁcant negative atten-
tion due to a serious adverse event resulting in the tragic death
of a patient (Marshall, 1999). Several studies have demonstrated
that a CTL mediated immune response limits transgene expres-
sion from Ad vectors in the ocular environment of mice (Hoff-
man, Maguire, & Bennett, 1997; Reichel et al., 1998).
Nonetheless, the only two published ocular gene therapy clinical
trials performed to date have each used Ad as the gene therapy
vector (Campochiaro et al., 2006; Chevez-Barrios et al., 2005).
These studies warrant some discussion since it would appearthat gene transfer in murine ocular tissues is not a good predic-
tor of results achieved in humans.
In one ocular gene therapy clinical trial, twenty-eight patients
with advanced age-related macular degeneration were injected
intravitreally with a second-generation Ad vector (including dele-
tions in E1, E3 as well as E4; Fig. 1) expressing pigment epithe-
lium-derived factor. The dose of Ad utilized ranged from 106 to
109.5 per patient and no dose-limiting toxicities were documented,
although mild and transient intraocular inﬂammation that could
be clinically managed was observed in 25% of patients (Campochi-
aro et al., 2006). In another ocular gene therapy clinical trial an
early generation Ad expressing herpes simplex thymidine kinase
was administered intravitreally to eight children suffering from
retinoblastoma. Again, no dose-limiting toxicities were observed
even at concentrations as high as 1011 viral particles. Mild inﬂam-
mation that could be managed was however documented (Chevez-
Barrios et al., 2005).
Earlier studies performed in mice demonstrating ocular im-
mune responses associated with Ad were performed with the
so-called ‘‘ﬁrst-generation” Ad vectors (Hoffman et al., 1997).
These vectors retained approximately 80% of the adenovirus gen-
ome (Fig. 1). Low-level expression of viral proteins from the ma-
jor later promoter (MLP) was attributed to a CTL mediated
immune response that led to loss of transgene expression. To ad-
dress the barrier of vector-associated immune responses, as
mentioned above, novel adenovirus vector systems have been
developed that do not generate a transgene-limiting immune re-
sponse in animals. These vectors were initially referred to as
‘encapsidated adenovirus minichromosomes’, ‘gutted’ or ‘gutless’
vectors but they are now more generally referred to as Helper-
dependent adenovirus (Hd-Ad) vectors (Parks et al., 1996). Hd-
Ad vectors contain only the Ad inverted terminal repeats that
are necessary for DNA replication and the Ad packaging signal
necessary for encapsidation of the recombinant genome into pre-
formed capsids. Hence, Hd-Ad vectors are devoid of all Ad genes
and hence similar in structure to recombinant AAV but with a
36 Kb cloning capacity instead of 4.8 Kb (Fig. 1). Importantly,
the absence of viral genes should theoretically abrogate the
low levels of gene expression from the MLP, products of which
lead to activation of CTLs from ﬁrst generation Ad vectors.
Hd-Ad vectors have been used to reduce the rate of photorecep-
tor degeneration in rd1 mice (Kumar-Singh & Farber, 1998). Initial
versions of Hd-Ad vectors were contaminated with helper-virus
that signiﬁcantly contributed to immune-mediated clearance of
transgene-containing cells. Those issues have been signiﬁcantly re-
solved by improvements in vector design and puriﬁcation tech-
niques (Palmer & Ng, 2003). Moreover, since those earlier studies
and other similar studies were performed in neonatal animals, they
are not directly relevant to treatment of RP in humans, as was dis-
cussed above. Two recent studies using Hd-Ad vectors in the retina
have had very signiﬁcant success in terms of long-term transgene
expression, in one study lasting more than one year, the latest time
point studied (Kreppel, Luther, Semkova, Schraermeyer, & Koch-
anek, 2002; Lamartina et al., 2007). Importantly, in non-ocular tis-
sues, where Hd-Ad vectors have had the greatest application thus
far, gene expression has been shown to persist for the ‘life-time’
of the animal (Kim, Jozkowicz, Piedra, Oka, & Chan, 2001). More-
over, Hd-Ad vectors persist in the brain and can be readministered
even in a preimmunized animal (Barcia et al., 2007). Ironically,
while the retinal gene therapy ﬁeld generally focuses on the neces-
sity of long-term transgene expression, the ability to readminister
the vector makes available the opportunity to explore the possibil-
ity of designing safer Phase I/II clinical trials. This may be achieved
by delivering therapeutic genes with the intention of short term
transgene expression that will naturally be ‘turned off’, should ad-
verse events begin to take place.
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apparent lack of a signiﬁcant immune response relative to ﬁrst
generation Ad vectors. However, the development of Hd-Ad vec-
tors that persist in the retina in terms of transgene expression
begs the question that the ﬁeld of ocular gene therapy once
again takes a close look at Ad, and more speciﬁcally at Hd-Ads.
Signiﬁcantly, a case is not being presented here for exclusive
use of Hd-Ads instead of AAV or Lv, but rather that Hd-Ad may
be an alternative vector to add to the ocular gene therapy vector
toolbox.
6. Non-viral vectors
Nobel Laureate Peter Medawar described a virus as a piece of
nucleic acid surrounded by bad news (Oldstone, 1998). While the
discussions above address the barriers to generating an optimal
viral gene transfer vector, introduction of large amounts of for-
eign protein such as the viral coat proteins whether they be from
Ad, AAV or Lv are likely to generate transient inﬂammatory re-
sponses that could exacerbate retinal disease and further com-
promise this delicate neuronal tissue. Hence, a preferred
approach would include the use of a non-viral vector that could
efﬁciently transduce retinal cells and achieve persistent trans-
gene expression. Such vectors are likely not to be as restrictive
in transgene cloning capacity and hence delivery of entire geno-
mic fragments containing all native gene regulatory elements
may be considered. Relative to viral vectors, non-viral gene
transfer to ocular or to any post-mitotic cells in vivo is currently
extremely inefﬁcient and attempts to rescue models of retinal
degeneration using such vectors have thus far not been success-
ful. However, non-viral reporter gene transfer rivaling levels
achieved by viral gene transfer has been reported by two groups
thus far, one approach using DNA encapsulating liposomes
(Zhang, Schlachetzki, Li, Boado, & Pardridge, 2003; Zhu, Zhang,
& Pardridge, 2002; Zhu et al., 2004) and another using a DNA-
compacting peptide (Farjo, Skaggs, Quiambao, Cooper, & Naash,
2006). Interestingly, both these studies yielded data that needs
to be somehow reconciled with previous studies describing the
use of viral vectors in the retina. As discussed below, in both
these approaches it appears that localization of the transgene
product delivered by non-viral vectors is either different from
that observed using viral vectors or there are as yet some unex-
plainable factors at play.
Zhang et al. intravenously delivered 85 nm immunoliposomes
targeted to the human insulin receptor to achieve non-invasive
transfer of genes across the blood retinal barrier of non-human pri-
mates (Zhang et al., 2003). These immunoliposomes encapsulated
a lacZ gene regulated by a 2.2 Kb bovine rod opsin promoter. The
study reported b-galactosidase activity in a large number of ocular
tissues including RPE, photoreceptors, lens, iris, cornea, ganglion
cells etc. Indeed, b-galactosidase activity was present to varying
degrees in a large number of ocular cells and absent in non-ocular
cells or non-ocular tissues such as brain, heart and lung. While
there has been considerable debate whether a 2.2 Kb opsin pro-
moter is rod speciﬁc, this is the only study describing organ speciﬁc
gene expression from an otherwise previously considered photore-
ceptor-speciﬁc promoter. These same investigators also utilized
85 nm immunoliposomes targeting the transferrin receptor to de-
liver genes across the blood retinal barrier in mice (Zhu et al.,
2004). In this latter case the investigators localized b-galactosidase
activity to the RPE, iris and ciliary body when using the same
2.2 Kb bovine opsin promoter. Use of the GFAP promoter also led
to unanticipated localization of b-galactosidase activity in the
RPE (Zhu et al., 2002). While extremely promising, immunolipo-
some mediated gene delivery across the blood retinal or blood
brain barrier appears to be highly technically demanding and hashence thus far not been widely replicated or used by other
investigators.
Recently, Farjo et al. (Farjo et al., 2006) demonstrated non-vir-
al gene transfer to photoreceptors at levels equivalent to or great-
er than viral gene transfer. In this study the investigators
compacted DNA into nanoparticles using a peptide containing a
cysteine residue coupled to poly ethylene glycol (PEG) followed
by 30 lysines (CK30). Such nanoparticles appeared as rods with
a minor diameter of less than 8 nm, signiﬁcantly less than the
25 nm diameter of the nuclear membrane pore (Dworetzky &
Feldherr, 1988; Feldherr & Akin, 1991), allowing the nanoparticles
to readily enter the nucleus (Liu et al., 2003). Following subretinal
administration of CK30, GFP localization by direct ﬂuorescence
indicated that GFP was present extensively in the outer nuclear
layer (photoreceptor cell bodies) and photoreceptor outer seg-
ments and absent from the inner photoreceptor segments (Farjo
et al., 2006). This pattern of GFP localization contrasts with that
observed using viral vectors, where typically the inner segments
are also GFP-positive and more so than the outer segments (Cash-
man et al., 2007; Khani et al., 2007). Transgenic mice expressing
GFP in photoreceptors also contain GFP in the inner segments
(Nour, Quiambao, Al-Ubaidi, & Naash, 2004). Furthermore, anti-
body mediated detection (immunoﬂuorescence) of GFP indicated
that CK30-compacted GFP delivered to the subretinal space re-
sulted in GFP expression exclusively to the outer nuclear layer
with no antibody signal in the outer or inner segments. Moreover,
while immunoﬂuorescence indicated a perinuclear location for re-
combinant GFP, direct ﬂuorescence indicated a nuclear location
for this same protein. Clearly this study would suggest that there
are major differences in patterns and locations of transgene
expression between viral vectors and some non-viral vectors in
the retina. These differences between viral and non-viral gene
delivery methods are intriguing and further investigation is nec-
essary to reconcile these apparent contradictions. CK30 particles
appear to be able to transduce non-dividing cells in culture (Liu
et al., 2003), however, evidence that they do so in vivo in post-mi-
totic tissues is extremely limited. Nonetheless, the studies per-
formed in the retina are interesting given that CK30
nanoparticles are currently being utilized in clinical trials for
treatment of cystic ﬁbrosis (Konstan et al., 2004).
Another potential non-viral approach to deliver nucleic acids to
the retina includes the use of peptides with cell penetrating prop-
erties such as peptide for ocular delivery (POD). Recently, Johnson et
al. have shown that POD can rapidly translocate across cell plasma
membranes in vitro and in vivo and deliver small and large mole-
cules into the photoreceptors, RPE, ganglion cells etc. (Johnson,
Cashman, & Kumar-Singh, 2007). Delivery of large molecules such
as DNA into the nucleus has thus far only been achieved in human
embryonic retinoblasts in culture. The limitations in vivo appear to
be the intact nuclear membrane, which disintegrates during mito-
sis in vitro to allow access of DNA to the nucleus. Similar to POD,
other peptides tested in ocular tissues for potential of delivery of
heterologous molecules include the protein transduction domain
of human immunodeﬁciency virus (HIV) Tat (Barnett, Elangovan,
Bullok, & Piwnica-Worms, 2006; Cashman, Morris, & Kumar-Singh,
2003; Schorderet et al., 2005) and Herpes Simplex Virus VP22
(Cashman et al., 2002; Kretz, Wybranietz, Hermening, Lauer, &
Isenmann, 2003).
In addition to CK30, a variety of strategies to compact DNA and
reduce its gyration radius to below the limiting diameter of the nu-
clear membrane pore have been employed. For example, use of
poly(lactide-co-glycolide)/PLGA that can form nanoparticles of
approximately 140 nm has been shown to transduce RPE (Bejjani
et al., 2005). How such particles cross the intact nuclear membrane
pore of approximately 25 nm is not yet understood. In non-ocular
tissues the polymer polyethylenimine (PEI) has been one of the
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al., 1995), but again, the efﬁciency has been too low to achieve ther-
apeutic levels of gene expression in vivo. Other promising non-viral
methods include in vivo electroporation (Chalberg, Genise, Vollrath,
& Calos, 2005) or electron avalanche transfection (Chalberg et al.,
2006). Again, each of these methods, while promising, need signif-
icant improvements prior to their potential use in the clinic.
Finally, while non-viral gene delivery has signiﬁcant advantages
over viral gene delivery, the therapeutic DNA is still likely to face
challenges from the immune system. Several sensors of single
stranded and double stranded DNA are present as part of the innate
immune response repertoires of cells. These sensors are located in
the endosomes e.g. Toll-like receptor (TLR) 9 (Akira, Uematsu, &
Takeuchi, 2006) as well as cytoplasmically, e.g. DAI (Takaoka et
al., 2007). Engagement of TLRs initiates a signaling cascade of
events that leads to induction of interferon-regulated factors and
transcription factors such as NF-jB. This cascade ultimately leads
to the production of type I interferon and proinﬂammatory cyto-
kines. The methods employed by host DNA to protect itself from
factors such as DAI are not yet understood. Caveats regarding these
well known responses need to be considered, especially in the con-
text of non-viral gene delivery to the retina.7. A Signiﬁcant need for further development of retinal gene
transfer vectors
Although the barriers referred to above do not exclude the use of
currently available viral vectors in human ocular gene therapy and
clinical trials are alreadyunderway, theydopoint toone thing: there
is an urgent need for better and safer gene delivery vectors. This
opinion is echoed in the 1995 Report and recommendations of the pa-
nel to assess the NIH investment in research on gene therapy by Stuart
Orkin and Arno Motulsky (available on NIH website http://
www.nih.gov/news/panelrep.html). The authors of this report con-
cluded that a major obstacle to gene therapy is the ‘‘shortcomings
in all current gene transfer vectors”. Their recommendations are that
‘‘efforts need to be applied to improving vectors for gene delivery,
enhancing and maintaining high level expression of genes transferred
to somatic cells, achieving tissue-speciﬁc and regulated expression of
transferred genes, and directing gene transfer to speciﬁc cell types.” As
discussed above, there is no evidence as yet that currently available
vectors are ideal for gene transfer in humans. Despite this, signiﬁ-
cantly fewer resources are invested in vector development relative
to attempted rescue of retinal disease models using compromised
vectors that are readily available or simply using vectors that were
developed by investigators with interests in non-ocular diseases
with a goal of addressing only the needs of those other organ sys-
tems. Consideration of retinal physiology is critical for the develop-
ment of vectors speciﬁcally for the retina, as was applied recently in
the design of Ad vectors aimed at improving photoreceptor trans-
ductionbysystematically reducing the interactionsbetweenAdcoat
proteins and RPE (Cashman et al., 2007).8. A case for inclusion of Hd-Ads in the ocular gene therapy
vector toolbox
Helper-dependent adenovirus vectors have a 36 Kb cloning
capacity, do not generally integrate and hence, theoretically,
should not cause insertional mutagenesis (Kumar-Singh & Cham-
berlain, 1996; Kumar-Singh & Farber, 1998; Morsy et al., 1998;
Parks et al., 1996). Hd-Ad vectors can be designed to integrate
site-speciﬁcally (Wang & Lieber, 2006) or allow for long-term epi-
somal transgene expression in the retina (Lamartina et al., 2007)
and can be readministered if necessary (Barcia et al., 2007).
Hd-Ad vectors have been found to be safe in non-human primates(Morral et al., 1999). At least two human ocular gene therapy trials
have validated ﬁrst generation Ad as being a safe vector (Campo-
chiaro et al., 2006; Chevez-Barrios et al., 2005). Data from several
hundred additional Ad-mediated gene transfer clinical trials in
non-ocular tissues indicate that it is a relatively safe vector (Edel-
stein, Abedi, & Wixon, 2007). However, Hd-Ad vectors transduce
primarily the RPE and not the photoreceptors. First generation
Ad5 vectors can be engineered to target photoreceptors (Cashman
et al., 2007) but these do not persist in transgene expression. Ad5
capsid proteins are typically used during the construction of Hd-Ad
vectors and hence Hd-Ad vectors based on Ad5 are potential candi-
dates for gene delivery to the RPE (Kreppel et al., 2002). It is tempt-
ing to suggest that retargeting of Hd-Ad vectors to the
photoreceptors where necessary can be simply achieved by using
a helper-virus derived from an Ad5 modiﬁed to target photorecep-
tors. Then, one may have in hand a vector with all of the properties
of the ideal gene transfer vector for RPE as well as photoreceptor
cells.
9. Concluding remarks
Here I have described just some of the major vector-associated
barriers faced by investigators in the retinal gene therapy ﬁeld. As
of now, there is no evidence that one vector is favorable over any
other, although a case is presented here for further consideration
of Ad as a potential vector for ocular gene therapy. The case for
Ad is presented not to claim that Ad is superior to AAV or Lv but
simply to reintroduce a vector that has not been generally discussed
or well utilized by the ocular gene therapy community. Clearly,
there are risks involved in any new endeavor and developing genet-
ic therapy for substantially debilitating diseases such as blindness
warrants pushing the envelope of risk. However, there is substan-
tial data in the retinal gene therapy literature that needs to be rec-
onciled in order to move the ﬁeld forward. Much of this data
indicates that preclinical success is focused on utilizing readily
available vectors to rescue animal models at the expense of vector
development that are relevant in the long-term to human ocular
gene therapy. General enthusiasm in the retinal gene therapy com-
munity that gene therapy for some rare retinal degenerations is
imminent is well founded but whether the current studies will lead
to rapid development of therapies for ocular gene therapy in gen-
eral will require novel solutions to the barriers described herein.
Note added in proof
Recently, Phase I data for two of the three LCA clinical trials has
been published (Bainbridge et al., 2008; Maguire et al., 2008). Also,
a recent study suggests that the limited 4.8 Kb capacity of AAV2
can be exceeded by AAV5 (Allocca et al., 2008).
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